Centre for Addiction and Mental Health

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

129

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 31

Phase 21

Preclinical1

By Therapeutic Area

top 1

Metabolic & Endocrine

133%

R&D Momentum

63/100

Pipeline Velocity

25/100

Trial Completion Rate

86/100

Pipeline Concentration

56/100

Pipeline Freshness

62/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 17, 2026

Active, not recruiting

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study

Sep 10, 2026

Recruiting

Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis: An Exploratory Multi-Methods Study

Earlier

Aug 28, 2026TrialIdentifying Biomarkers of Response to Digital Interventions for Mood Disorders

Aug 28, 2026TrialDoes tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia

Aug 26, 2026TrialSwitching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial

Aug 26, 2026TrialThe Effects of Adjunctive Transcranial Direct Current Stimulation on Treatment Adherence in Schizophrenia

Aug 22, 2026TrialEvaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Aug 21, 2026TrialEffectiveness of an Integrated Care Pathway for Adolescent Depression: A Quasi-experimental, Multi-site, Cluster Controlled Trial

3 more events

Aug 7, 2026TrialPsilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism

Jul 31, 2026TrialTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

Jul 31, 2026TrialImaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

HumalogPreclinical

Unknown / Other

Smoking Cessation

Nicotine mouthsprayPhase 3

Trial

Varenicline BIDPhase 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)